The University of Chicago Header Logo

Connection

George Bakris to Kidney

Back to Details
This is a "connection" page, showing publications George Bakris has written about Kidney.
George Bakris
Connection Strength
14.607
Kidney
  1. Initial Drops in Glomerular Filtration Rate with Certain Drug Classes Retard Kidney Disease Progression. Am J Nephrol. 2022; 53(7):513-515.
    View in: PubMed
    Score: 0.556
  2. Blood and Urine Biomarkers Predicting Worsening Kidney Function in Patients with Type 2 Diabetes Post-Acute Coronary Syndrome: An Analysis from the EXAMINE Trial. Am J Nephrol. 2021; 52(12):969-976.
    View in: PubMed
    Score: 0.536
  3. Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial. Clin J Am Soc Nephrol. 2020 12 07; 15(12):1705-1714.
    View in: PubMed
    Score: 0.499
  4. Catheter-Based Renal Denervation for Resistant Hypertension: Will It Ever Be Ready for "Prime Time"? Am J Hypertens. 2017 Sep 01; 30(9):841-846.
    View in: PubMed
    Score: 0.399
  5. Current Status of Renal Denervation in Hypertension. Curr Cardiol Rep. 2016 11; 18(11):107.
    View in: PubMed
    Score: 0.377
  6. Renal Denervation: a Field in Flux. Curr Hypertens Rep. 2016 Jul; 18(7):56.
    View in: PubMed
    Score: 0.368
  7. Impact of Renal Denervation on Patients With Obstructive Sleep Apnea and Resistant Hypertension - Insights From the SYMPLICITY HTN-3 Trial. Circ J. 2016 May 25; 80(6):1404-12.
    View in: PubMed
    Score: 0.364
  8. Effect of Catheter-Based Renal Denervation on Morning and Nocturnal Blood Pressure: Insights From SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan. Hypertension. 2015 Dec; 66(6):1130-7.
    View in: PubMed
    Score: 0.350
  9. Renal denervation for the treatment of resistant hypertension: review and clinical perspective. Am J Physiol Renal Physiol. 2015 Oct 01; 309(7):F583-94.
    View in: PubMed
    Score: 0.345
  10. Renal denervation for resistant hypertension and beyond. Adv Chronic Kidney Dis. 2015 Mar; 22(2):133-9.
    View in: PubMed
    Score: 0.336
  11. Renal Denervation After SYMPLICITY HTN-3: Where Do We Go? Can J Cardiol. 2015 May; 31(5):642-8.
    View in: PubMed
    Score: 0.330
  12. The future of renal denervation in resistant hypertension. Curr Hypertens Rep. 2014 Dec; 16(12):494.
    View in: PubMed
    Score: 0.330
  13. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015 Jan 21; 36(4):219-27.
    View in: PubMed
    Score: 0.329
  14. The future of interventional management of hypertension: threats and opportunities. Curr Vasc Pharmacol. 2014 Jan; 12(1):69-76.
    View in: PubMed
    Score: 0.310
  15. Renal denervation and left ventricular mass regression: a benefit beyond blood pressure reduction? J Am Coll Cardiol. 2014 May 13; 63(18):1924-5.
    View in: PubMed
    Score: 0.308
  16. Interventional cardiology: Indications for renal denervation: a balanced approach? Nat Rev Cardiol. 2013 Aug; 10(8):434-6.
    View in: PubMed
    Score: 0.297
  17. Timing and efficacy of alternative methods of sympathetic blockade. Curr Hypertens Rep. 2012 Oct; 14(5):455-61.
    View in: PubMed
    Score: 0.284
  18. The promise of renal denervation. Cleve Clin J Med. 2012 Jul; 79(7):498-500.
    View in: PubMed
    Score: 0.279
  19. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol. 2012 Sep; 35(9):528-35.
    View in: PubMed
    Score: 0.276
  20. Do fibrates truly preserve kidney function? Nat Rev Endocrinol. 2011 Mar; 7(3):130-1.
    View in: PubMed
    Score: 0.253
  21. Hypertension following kidney injury. J Clin Hypertens (Greenwich). 2010 Sep; 12(9):727-30.
    View in: PubMed
    Score: 0.246
  22. Racial differences in kidney function among individuals with obesity and metabolic syndrome: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2010 Mar; 55(3 Suppl 2):S4-S14.
    View in: PubMed
    Score: 0.237
  23. The kidney, hypertension, and remaining challenges. Med Clin North Am. 2009 May; 93(3):697-715, Table of Contents.
    View in: PubMed
    Score: 0.224
  24. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009 Jun; 75(12):1272-1277.
    View in: PubMed
    Score: 0.223
  25. Renal hemodynamic changes in heart failure. Heart Fail Clin. 2008 Oct; 4(4):411-23.
    View in: PubMed
    Score: 0.215
  26. Changes in kidney function following heart failure treatment: focus on renin-angiotensin system blockade. Heart Fail Clin. 2008 Oct; 4(4):425-38.
    View in: PubMed
    Score: 0.215
  27. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int. 2006 Oct; 70(7):1223-33.
    View in: PubMed
    Score: 0.185
  28. Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics. Hypertension. 2004 Mar; 43(3):573-7.
    View in: PubMed
    Score: 0.156
  29. Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression. Diabetes Care. 2023 09 01; 46(9):1574-1586.
    View in: PubMed
    Score: 0.151
  30. The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: Post hoc analysis of the FIDELITY study. Diabetes Obes Metab. 2023 10; 25(10):2989-2998.
    View in: PubMed
    Score: 0.150
  31. Key questions regarding the SYMPLICITY HTN-3 trial - Authors' reply. Lancet. 2023 04 22; 401(10385):1337-1338.
    View in: PubMed
    Score: 0.148
  32. Novel Therapies on the Horizon of Hypertension Management. Am J Hypertens. 2023 02 13; 36(2):73-81.
    View in: PubMed
    Score: 0.146
  33. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022 12 01; 45(12):3075-3090.
    View in: PubMed
    Score: 0.144
  34. A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes. Kidney Int. 2023 01; 103(1):196-206.
    View in: PubMed
    Score: 0.143
  35. Aldosterone excess and cardiorenal risk: more common than appreciated. Eur Heart J. 2022 10 11; 43(38):3792-3793.
    View in: PubMed
    Score: 0.142
  36. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2022 11; 102(5):974-989.
    View in: PubMed
    Score: 0.142
  37. Mineralocorticoid Receptor Antagonists-Evidence for Kidney Protection, Trials With Novel Agents. Adv Chronic Kidney Dis. 2021 07; 28(4):371-377.
    View in: PubMed
    Score: 0.130
  38. Reductions in albuminuria with SGLT2 inhibitors: a marker for improved renal outcomes in patients without diabetes? Lancet Diabetes Endocrinol. 2020 07; 8(7):553-555.
    View in: PubMed
    Score: 0.121
  39. Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. J Am Soc Nephrol. 2020 05; 31(5):1128-1139.
    View in: PubMed
    Score: 0.120
  40. Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. Diabetes Care. 2020 02; 43(2):446-452.
    View in: PubMed
    Score: 0.116
  41. Kidney injury is not prevented by hydration alone. Eur Heart J. 2019 10 07; 40(38):3179-3181.
    View in: PubMed
    Score: 0.115
  42. Heart Failure and Changes in Kidney Function: Focus on Understanding, Not Reacting. Heart Fail Clin. 2019 Oct; 15(4):455-461.
    View in: PubMed
    Score: 0.114
  43. Renal hemodynamics in radiocontrast medium-induced renal dysfunction: A role for dopamine-1 receptors. Kidney Int. 1999 Jul; 56(1):206-10.
    View in: PubMed
    Score: 0.113
  44. Assessing kidneys that may be fragile. Postgrad Med. 1998 Nov; 104(5):31.
    View in: PubMed
    Score: 0.108
  45. Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function. Circulation. 2018 10 09; 138(15):1537-1550.
    View in: PubMed
    Score: 0.108
  46. Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study. Am J Nephrol. 2018; 47(1):40-47.
    View in: PubMed
    Score: 0.102
  47. Preservation of renal function: the spectrum of effects by calcium-channel blockers. Nephrol Dial Transplant. 1997 Nov; 12(11):2244-50.
    View in: PubMed
    Score: 0.101
  48. Combined effects of an angiotensin converting enzyme inhibitor and a calcium antagonist on renal injury. J Hypertens. 1997 Oct; 15(10):1181-5.
    View in: PubMed
    Score: 0.100
  49. Renal components of the hypertensive syndrome. J Cardiovasc Risk. 1997 Aug; 4(4):271-7.
    View in: PubMed
    Score: 0.099
  50. Renal Targeted Therapies of Antihypertensive and Cardiovascular Drugs for Patients With Stages 3 Through 5d Kidney Disease. Clin Pharmacol Ther. 2017 Sep; 102(3):450-458.
    View in: PubMed
    Score: 0.099
  51. Is the level of arterial pressure reduction important for preservation of renal function. Nephrol Dial Transplant. 1996 Dec; 11(12):2383-4.
    View in: PubMed
    Score: 0.095
  52. Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS. Diabetes Care. 2016 Dec; 39(12):2304-2310.
    View in: PubMed
    Score: 0.094
  53. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPLICITY HTN-3 trial. J Am Soc Hypertens. 2015 Oct; 9(10):769-779.
    View in: PubMed
    Score: 0.086
  54. Renal effects of oral prostaglandin supplementation after ibuprofen in diabetic subjects: a double-blind, placebo-controlled, multicenter trial. J Am Soc Nephrol. 1995 Mar; 5(9):1684-8.
    View in: PubMed
    Score: 0.084
  55. Hypertension and new treatment approaches targeting the sympathetic nervous system. Curr Opin Pharmacol. 2015 Apr; 21:20-4.
    View in: PubMed
    Score: 0.083
  56. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens. 2014 May; 8(5):330-9.
    View in: PubMed
    Score: 0.078
  57. Microalbuminuria as a risk predictor in diabetes: the continuing saga. Diabetes Care. 2014; 37(3):867-75.
    View in: PubMed
    Score: 0.077
  58. Metformin nephrotoxicity insights: will they change clinical management? J Diabetes. 2014 Mar; 6(2):111-2.
    View in: PubMed
    Score: 0.077
  59. International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension. J Am Coll Cardiol. 2013 Dec 03; 62(22):2031-45.
    View in: PubMed
    Score: 0.076
  60. Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria. Kidney Int. 1993 Jun; 43(6):1210-8.
    View in: PubMed
    Score: 0.074
  61. Renal effects of antihypertensive medications: an overview. J Clin Pharmacol. 1993 May; 33(5):392-9.
    View in: PubMed
    Score: 0.074
  62. Hypertension in diabetic patients. An overview of interventional studies to preserve renal function. Am J Hypertens. 1993 Apr; 6(4):140S-147S.
    View in: PubMed
    Score: 0.073
  63. Risk for renal injury in diabetic hypertensive patients. The physiologic basis for blood pressure control. Postgrad Med. 1992 Feb 15; 91(3):77-80, 83-4.
    View in: PubMed
    Score: 0.068
  64. Risk for renal injury in diabetic hypertensive patients. Pharmacologic approaches. Postgrad Med. 1992 Feb 15; 91(3):87-91, 94-5.
    View in: PubMed
    Score: 0.068
  65. Renal outcomes in hypertensive Black patients at high cardiovascular risk. Kidney Int. 2012 Mar; 81(6):568-76.
    View in: PubMed
    Score: 0.067
  66. The effects of calcium antagonists on renal hemodynamics, urinary protein excretion, and glomerular morphology in diabetic states. J Am Soc Nephrol. 1991 Aug; 2(2 Suppl 1):S21-9.
    View in: PubMed
    Score: 0.065
  67. Renal effects of calcium antagonists in diabetes mellitus. An overview of studies in animal models and in humans. Am J Hypertens. 1991 Jul; 4(7 Pt 2):487S-493S.
    View in: PubMed
    Score: 0.065
  68. Telmisartan in incipient and overt diabetic renal disease. J Nephrol. 2011 May-Jun; 24(3):263-73.
    View in: PubMed
    Score: 0.064
  69. Pathogenesis and clinical physiology of hypertension. Cardiol Clin. 2010 Nov; 28(4):545-59.
    View in: PubMed
    Score: 0.062
  70. Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am J Physiol. 1990 Jan; 258(1 Pt 2):F115-20.
    View in: PubMed
    Score: 0.059
  71. Effects of angiotensin II receptor blockers on diabetic nephropathy. J Hypertens Suppl. 2009 Jul; 27(5):S15-21.
    View in: PubMed
    Score: 0.057
  72. The message for World Kidney Day 2009. Hypertension and kidney disease: a marriage that should be prevented. Nephron Clin Pract. 2009; 111(2):c155-8.
    View in: PubMed
    Score: 0.055
  73. The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. Am J Nephrol. 2009; 30(1):95-8.
    View in: PubMed
    Score: 0.055
  74. Calcium antagonists: Do they equally protect against kidney injury? Kidney Int. 2008 Apr; 73(7):795-6.
    View in: PubMed
    Score: 0.052
  75. Executive summary: Kidney Early Evaluation Program (KEEP) 2007 Annual Data Report. Am J Kidney Dis. 2008 Apr; 51(4 Suppl 2):S1-2.
    View in: PubMed
    Score: 0.052
  76. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis. 2007 Jan; 49(1):12-26.
    View in: PubMed
    Score: 0.048
  77. The renal, forearm, and hormonal responses to standing in the presence and absence of propranolol. Circulation. 1986 Nov; 74(5):1061-5.
    View in: PubMed
    Score: 0.047
  78. Beta blockers in the management of chronic kidney disease. Kidney Int. 2006 Dec; 70(11):1905-13.
    View in: PubMed
    Score: 0.047
  79. Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials. BMJ Open. 2024 Mar 19; 14(3):e076444.
    View in: PubMed
    Score: 0.039
  80. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues. Semin Nephrol. 2004 Mar; 24(2):168-75.
    View in: PubMed
    Score: 0.039
  81. Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria. Circulation. 2024 02 06; 149(6):450-462.
    View in: PubMed
    Score: 0.038
  82. Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression. J Am Soc Nephrol. 2023 12 01; 34(12):2025-2038.
    View in: PubMed
    Score: 0.038
  83. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant. 2023 08 31; 38(9):2041-2051.
    View in: PubMed
    Score: 0.038
  84. Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials. J Am Heart Assoc. 2023 07 04; 12(13):e028516.
    View in: PubMed
    Score: 0.037
  85. Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering. BMJ Open Diabetes Res Care. 2023 06; 11(3).
    View in: PubMed
    Score: 0.037
  86. Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials. Kidney Int. 2023 07; 104(1):181-188.
    View in: PubMed
    Score: 0.037
  87. Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial. Am J Kidney Dis. 2023 07; 82(1):84-96.e1.
    View in: PubMed
    Score: 0.037
  88. Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study. Nephrol Dial Transplant. 2023 02 13; 38(2):372-383.
    View in: PubMed
    Score: 0.036
  89. Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria. J Am Coll Cardiol. 2022 11 01; 80(18):1721-1731.
    View in: PubMed
    Score: 0.036
  90. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial. Lancet. 2022 10 22; 400(10361):1405-1416.
    View in: PubMed
    Score: 0.035
  91. Glucose-lowering treatment patterns in patients with diabetic kidney disease. Am J Manag Care. 2022 08 01; 28(8):e301-e307.
    View in: PubMed
    Score: 0.035
  92. Renal handling of albumin: a critical review of basic concepts and perspective. Am J Kidney Dis. 2002 May; 39(5):899-919.
    View in: PubMed
    Score: 0.034
  93. Kidney function assessment and endpoint ascertainment in clinical trials. Eur Heart J. 2022 04 06; 43(14):1379-1400.
    View in: PubMed
    Score: 0.034
  94. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022 Feb 10; 43(6):474-484.
    View in: PubMed
    Score: 0.034
  95. Novel Renal Autologous Cell Therapy for Type 2 Diabetes Mellitus Chronic Diabetic Kidney Disease: Clinical Trial Design. Am J Nephrol. 2022; 53(1):50-58.
    View in: PubMed
    Score: 0.034
  96. The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Post Hoc Analysis of the SONAR Randomized Trial. Clin J Am Soc Nephrol. 2021 12; 16(12):1824-1832.
    View in: PubMed
    Score: 0.033
  97. Choices and goals in the treatment of the diabetic hypertensive patient. Curr Hypertens Rep. 2001 Oct; 3(5):387-91.
    View in: PubMed
    Score: 0.033
  98. Renal denervation in hypertension patients: Proceedings from an expert consensus roundtable cosponsored by SCAI and NKF. Catheter Cardiovasc Interv. 2021 09; 98(3):416-426.
    View in: PubMed
    Score: 0.033
  99. Comparative effects of selective T- and L-type calcium channel blockers in the remnant kidney model. Hypertension. 2001 May; 37(5):1268-72.
    View in: PubMed
    Score: 0.032
  100. Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial. Diabetes Obes Metab. 2021 02; 23(2):561-568.
    View in: PubMed
    Score: 0.031
  101. Association of Arterial Stiffness With Kidney Function Among Adults Without Chronic Kidney Disease. Am J Hypertens. 2020 11 03; 33(11):1003-1010.
    View in: PubMed
    Score: 0.031
  102. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int. 2000 Nov; 58(5):2084-92.
    View in: PubMed
    Score: 0.031
  103. The future of clinical trials in chronic renal disease: outcome of an NIH/FDA/Physician Specialist Conference. Evaluation of Clinical Trial Endpoints in Chronic Renal Disease Study Group. J Clin Pharmacol. 2000 Aug; 40(8):815-25.
    View in: PubMed
    Score: 0.031
  104. Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation. Kidney Int. 2000 Apr; 57(4):1651-61.
    View in: PubMed
    Score: 0.030
  105. Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial. Circulation. 2020 02 04; 141(5):407-410.
    View in: PubMed
    Score: 0.029
  106. The role of combination antihypertensive therapy and the progression of renal disease hypertension: looking toward the next millennium. Am J Hypertens. 1998 Oct; 11(10):158S-162S.
    View in: PubMed
    Score: 0.027
  107. Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. Diabetes Obes Metab. 2018 06; 20(6):1369-1376.
    View in: PubMed
    Score: 0.026
  108. Role of vasopressin in essential hypertension: racial differences. J Hypertens. 1997 May; 15(5):545-50.
    View in: PubMed
    Score: 0.024
  109. Intensive Hemodialysis and Potential Risks With Increasing Treatment. Am J Kidney Dis. 2016 Nov; 68(5S1):S51-S58.
    View in: PubMed
    Score: 0.024
  110. Regression to the Mean in SYMPLICITY HTN-3: Implications for Design and Reporting of Future Trials. J Am Coll Cardiol. 2016 11 01; 68(18):2016-2025.
    View in: PubMed
    Score: 0.024
  111. Proceedings from Duke resistant hypertension think tank. Am Heart J. 2014 Jun; 167(6):775-88.e1.
    View in: PubMed
    Score: 0.020
  112. Antihypertensive therapy and progression of diabetic renal disease. J Cardiovasc Pharmacol. 1994; 23 Suppl 1:S34-8.
    View in: PubMed
    Score: 0.019
  113. Diabetic nephropathy. What you need to know to preserve kidney function. Postgrad Med. 1993 Apr; 93(5):89-90, 93-5, 99-100.
    View in: PubMed
    Score: 0.018
  114. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Soc Hypertens. 2011 Jul-Aug; 5(4):259-352.
    View in: PubMed
    Score: 0.016
  115. Role for intrarenal adenosine in the renal hemodynamic response to contrast media. J Lab Clin Med. 1987 Oct; 110(4):406-11.
    View in: PubMed
    Score: 0.013
  116. A role for calcium in radiocontrast-induced reductions in renal hemodynamics. Kidney Int. 1985 Feb; 27(2):465-8.
    View in: PubMed
    Score: 0.010
  117. Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis. 2003 Oct; 42(4):617-22.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.